A copper-delivering compound has cleared 42% of the toxic proteins that drive Alzheimer's disease in laboratory models, restored the brain's primary waste-removal system, and improved spatial learning by nearly 44% — a preclinical finding published June 15, 2026, in ACS Chemical Neuroscience with an unusual translational advantage: the compound has already been through human safety testing for two other neurological diseases.
The study, by researchers at Monash University's Monash Institute of Pharmaceutical Sciences (MIPS), establishes a new mechanistic pathway — one that targets not the amyloid-beta proteins themselves, but the brain's impaired ability to clear them.
